Want to see BDRX full AI Analyst Report?
BDRX Stock Chart & Stats
$0.87
-$0.08(-4.85%)
At close: 4:00 PM EDT
$0.87
-$0.08(-4.85%)
Day’s Range― - ―
52-Week Range$0.45 - $52.05
Previous Close$1.75
Volume25.39K
Average Volume (3M)7.11M
Market Cap
$473.58K
Enterprise Value$21.72B
Total Cash (Recent Filing)$3.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-50.00
Shares Outstanding4,193,917
10 Day Avg. Volume171,583
30 Day Avg. Volume7,112,427
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.03
Enterprise Value/Market Cap45.86K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-167.98K
Enterprise Value/Ebitda-4.64K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)$7.66K
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetMinimal debt gives Biodexa greater financial flexibility than a highly leveraged development-stage biotech. The stronger equity and asset base provide some capacity to continue advancing programs, although this benefit depends on containing losses and preserving capital.
Pipeline And Trial ExpansionProgress across MTX240 and the late-stage eRapa program broadens Biodexa’s potential sources of future clinical and commercial value. The Canadian trial expansion and early access program also extend development and patient-reach infrastructure beyond a single study.
Reduced Historical Cash OutflowThe substantial year-over-year reduction in operating cash outflow indicates improved cash discipline compared with 2024. If sustained alongside pipeline execution, lower burn could extend financing runway and reduce the frequency or size of capital raises needed to support development.
Bears Say
No Operating Revenue And Persistent LossesBiodexa remains pre-commercial, so its pipeline has not yet translated into recurring product revenue. Persistent operating and net losses limit internally generated funding, keep the company dependent on external capital, and make sustained profitability contingent on successful development and commercialization.
Ongoing Cash Burn And Rising R&D SpendingAccelerating late-stage oncology development is increasing the cash required to operate, while cash generation remains negative. This combination can shorten funding runway and raise dependence on additional financing before clinical programs produce licensing income, milestones, or product sales.
Future Equity Dilution RiskThe financing improves near-term liquidity but creates a substantial pool of immediately exercisable future warrants. If exercised, those instruments could increase the ADS share count and dilute existing holders, while signaling that continued pipeline funding may rely on equity-linked capital.
Biodexa Pharmaceuticals News
BDRX FAQ
What was Biodexa Pharmaceuticals’s price range in the past 12 months?
Biodexa Pharmaceuticals lowest stock price was $0.45 and its highest was $52.05 in the past 12 months.
What is Biodexa Pharmaceuticals’s market cap?
Biodexa Pharmaceuticals’s market cap is $473.58K.
When is Biodexa Pharmaceuticals’s upcoming earnings report date?
Biodexa Pharmaceuticals’s upcoming earnings report date is Apr 23, 2027 which is in 193 days.
How were Biodexa Pharmaceuticals’s earnings last quarter?
Biodexa Pharmaceuticals released its earnings results on Sep 11, 2026. The company reported $0 earnings per share for the quarter.
Is Biodexa Pharmaceuticals overvalued?
According to Wall Street analysts Biodexa Pharmaceuticals’s price is currently Overvalued.
Does Biodexa Pharmaceuticals pay dividends?
Biodexa Pharmaceuticals does not currently pay dividends.
What is Biodexa Pharmaceuticals’s EPS estimate?
Biodexa Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biodexa Pharmaceuticals have?
Biodexa Pharmaceuticals has 4,193,917 shares outstanding.
What happened to Biodexa Pharmaceuticals’s price movement after its last earnings report?
Biodexa Pharmaceuticals reported an EPS of $0 in its last earnings report. Following the earnings report the stock price went down -13.846%.
Which hedge fund is a major shareholder of Biodexa Pharmaceuticals?
Currently, no hedge funds are holding shares in BDRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
Technical Analysis
―
Indaptus Therapeutics
―
InMed Pharmaceuticals
―
Enveric Biosciences
―
CNS Pharmaceuticals
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.36% Other Institutional Investors
99.64% Public Companies and
Individual Investors